A multicenter phase I clinical trial (NCT04230265) to assess the universal CAR-T-cell platform (UniCAR) that was recently described to have efficient in vitro and in vivo activity against CD123+ AML is currently recruiting patients [16]. This evidence concerns the gene IL3RA and acute myeloid leukemia.